Literature DB >> 8806510

Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.

E K Franke1, J Luban.   

Abstract

The HIV-1 Gag polyprotein specifically incorporates the cellular peptidylprolyl isomerase cyclophilin A into virions. HIV-1 replication is inhibited by cyclosporine A, an immunosuppressive drug which binds with high affinity to cyclophilin A and precludes interaction with the Gag polyprotein. Using a panel of four drugs, including cyclosporine A, two nonimmunosuppressive analogues of cyclosporine A which bind to cyclophilin A but which cannot form a tertiary complex with the calcium-dependent phosphatase calcineurin, and the structurally unrelated immunosuppressant FK506, we demonstrated that the antiviral effect of cyclosporine A is not due to blockade of calcineurin-mediated signal transduction pathways. Rather, the effectiveness of cyclosporine A and related compounds at inhibiting HIV-1 replication correlates with cyclophilin A-binding affinity and with the ability to disrupt the interaction between cyclophilin A and the HIV-1 Gag polyprotein. These results support the contention that the Gag-cyclophilin A interaction is required for HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806510     DOI: 10.1006/viro.1996.0421

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

1.  HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Authors:  M Srivastava; M Cartas; T A Rizvi; S P Singh; D Serio; V S Kalyanaraman; H B Pollard; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.

Authors:  T Pushkarsky; G Zybarth; L Dubrovsky; V Yurchenko; H Tang; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 3.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 4.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1.

Authors:  Tsai-Yu Lin; Michael Emerman
Journal:  Virology       Date:  2008-08-03       Impact factor: 3.616

6.  The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.

Authors:  D Braaten; H Ansari; J Luban
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 7.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

Review 8.  Molecular evolution of the antiretroviral TRIM5 gene.

Authors:  Welkin E Johnson; Sara L Sawyer
Journal:  Immunogenetics       Date:  2009-02-24       Impact factor: 2.846

9.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells.

Authors:  Mingli Qi; Ruifeng Yang; Christopher Aiken
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.